Kliniska studier vid Tema Cancer

MAATEO. A phase 1 study in MDS, AML and ALL patients to evaluate safety, tolerability and efficacy of Karonudib

Stefan Deneberg

HOVON 150. A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acutemyeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy

Martin Jädersten

EVI-3: Combining Active and Passive DNA Hypomethylation. EVI-3: Combining Active and Passive DNA Hypomethylation A multicenter, randomized, parallel-group, placebo-controlled phase II study of the efficacy and safety of oral vitamin C supplement in combination with azacitidine in higher-risk MDS, CMML, and low-blast-count AML

Eva Hellström Lindberg

LD-VenEx. LD-VenEx Clinical Study Protocol: Phase 2 study of azacitidine in combination with low dose intensity venetoclax in patients with acute myeloid leukemia with integration of explorative multi-omics and ex vivo drug screening data

Martin Jädersten

MK3543-006-05 Shorespan-006. A Phase 3 Multi-Center, Randomized, Controlled Study to Assess the Safety and Efficacy of Bomedemstat (IMG-7289) versus Best Available Therapy (BAT) in Patients with Essential Thrombocythemia who are Resistant to or Intolerant of Hydroxyurea

Anna Ravn Landtblom

MEDAL. Monitoring for Early Detection of relapse in Acute myeloid Leukemia

Martin Jädersten

MK3543-007 (Shorespan-007). A phase 3, Randomized, Double-blind, Active.Comparator-Controlled Clinical Study to Evaluate the Efficacy and Safety of Bomedemstat (MK3543) versus Hydroxyurea in Cytoreductive Therapy Naive Essential thrombocythemia Partiocipants

Anna Ravn Landtblom

TAK-079-3002. A Phase 3, Randomized, Double-blind, Placebo-controlled Studyto Evaluate Efficacy and Safety of Mezagitamab SubcutaneousInjection in Participants with Chronic Primary ImmuneThrombocytopenia

Cecilia Karlström

Immunologiska lab-studier på patienter med KLL och andra hematol. In vitro studier av immunologiska funktioner hos patienter med kroniska lymfoproliferativa tumörsjukdomar (Myelom, lymfom, KLL) och MGOS: Extra blodprovstagning

Anders Österborg

BioLymph. Prospektiv studie av biologi, etiologi och överlevnad vid lymfom (BioLymph)

Karin Ekström Smedby

PRO-Hodgkin. Clinical investigation of PBS proton treatment in Hodgkin lymphoma patients

Lotta Hansson

POLAR BEAR-studien. R-MINI-CHOP versus R-MINI-CHP in combination with polatuzumab-vedotin, as primary treatment for patients with diffuse large B-cell lymphoma, ≥80 years, or frail ≥75 years – an open label randomized Nordic Lymphoma Group phase III trial - NLG-LBC7 (POLAR BEAR)

Sara Harrysson

DSA-LL-studien. Better and individualised therapy for patients with relapsing lymphoma and leukaemia

Björn Wahlin

ALLTogether-1. ALLTogether1– A Treatment study protocol of the ALLTogether Consortium for children and young adults (1-45 years of age) with newly diagnosed acute lymphoblastic leukaemia (ALL)

Joel Joelsson

PreVent-ACaLL. Short-term combined acalabrutinib and venetoclax treatment of newly diagnosed patients with CLL at high risk of infection and/or early treatment who do not fulfil IWCLL treatment criteria for treatmnet. A randomized study with extensive immune phenotyping

Jeanette Lundin

BGB3111-LTE1 Roll-overstudie. En öppen, multicenter, långsiktig förlängningsstudie av zanubrutinib (BGB-3111) hos patienter med Bcellsmaligniteter.

Björn Wahlin

MERLIN. Phase II multicenter clinical trial:Mosunetuzumab for Early Relapse of Follicular Lymphoma inthe Nordic countries

Björn Wahlin

BELLWAVE-011 (MK1026-011). A Phase 3, Randomized Study to Compare the Efficacy and Safety ofNemtabrutinib Versus Ibrutinib as 1L+ Therapy in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BELLWAVE-011)

Anders Österborg

HYPERION. Hyper-CVAD/MA for high-risk aggressive B-cell lymphomas: a single-centre academic phase II trial

Björn Wahlin

Golseek-1. A phase 3, multicenter, Randomized, Double-blind, Placebo-controlled study compairing the efficacy and safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP chemotherapy in participants with Previouslyu untreated High-risk large B-Cell lymphoma.

Kristina Sonnevi

MAGNETISMM-7-studien. A randomised, 2-arm, phase 3 study of elranatamab (PF-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma who are minimal residual disease-positive after undergoing autologous stem-cell transplantation

Katarina Uttervall

MajesTEC-7. A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) versus Daratumumab SC, Lenalidomide, and Dexamethasone (DRd) in Participants with Newly Diagnosed Multiple Myeloma Who are Either Ineligible or not Intended for Autologous Stem Cell Transplant as Initial Therapy

Katarina Uttervall

ODX-MM-001. A Phase I/IIa Study of ODX (OsteoDex) in Multiple Myeloma

Katarina Uttervall

A-EKG-HemA. Kardiovaskulära risker och mikropartiklarnas roll i en åldrade population av patienter med hemofili A under olika behandlingsregim

Roza Chaireti

Labmarkörer MPN-patienter . Labmarkörer som en del av riskbedömning för trombohemorrhagiska komplikationer hos patienter med myeloproliferativa sjukdomar

Roza Chaireti